Latest Ratios: P/E Ratio -3.9x · EV/EBITDA N/A · ROE -52.5%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $390M | $493M | $188M | $154M | — | — |
| Enterprise Value | $281M | $384M | $11M | $55M | — | — |
| P/E Ratio → | -3.88 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 3.81 | 4.86 | 1.17 | 1.94 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -52.5% | -52.5% | -43.7% | -210.0% | -47.6% | 6.5% |
| ROA | -46.8% | -46.8% | -37.4% | -113.8% | -35.3% | 6.0% |
| ROIC | — | — | — | — | -35.9% | — |
| ROCE | -57.5% | -57.5% | -45.9% | -176.5% | -41.6% | -0.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.08 | -1.10 | -1.25 | — | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | -0.09 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($109M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 9.05 | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Quick Ratio | 9.05 | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Cash Ratio | 8.82 | 8.82 | 9.04 | 4.92 | 0.11 | 2.68 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $94M | $75M | $33M | $17M | $17M |
Includes 30+ ratios · 5 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZURA stock.
Zura Bio Limited's current P/E ratio is -3.9x. This places it at the 50th percentile of its historical range.
Zura Bio Limited's return on equity (ROE) is -52.5%. The historical average is -69.5%.
Based on historical data, Zura Bio Limited is trading at a P/E of -3.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Pre-revenue cash burn
Metrics are mathematically derived from official filings.
Valuation Reflects Pipeline Speculation
ZURA's P/B ratio of 5.26, as reported in recent market data, is elevated relative to peers like DAWN (5.05) and KYMR (6.34), suggesting the market is pricing in significant future pipeline value despite the company's pre-revenue status and negative earnings.
The valuation multiples are not anchored to current earnings or cash flow, making traditional P/E and EV/EBITDA metrics irrelevant. The P/B ratio is the primary observable multiple, and its level indicates investors are assigning a substantial premium to the company's net assets, which are predominantly cash. This premium is a bet on the successful development and commercialization of its pipeline, not on current operational performance.
Liquidity Buffer Masks Burn Rate
Based on the company's most recent balance sheet, ZURA's current ratio of 12.90 is exceptionally high, but this static measure is misleading as it does not account for the accelerating quarterly cash burn of over $20 million.
The liquidity position appears fortress-like on a snapshot basis, with cash and equivalents dwarfing current liabilities. However, the critical metric is the runway this cash provides. With operating losses exceeding $25 million per quarter and no revenue, the high current ratio is a temporary state that will erode as the company funds its operations. The sustainability of this liquidity is entirely dependent on the pace of clinical development and future financing needs.
Negative Returns Reflect Development Phase
ZURA's ROE has been consistently negative, ranging from -5.5% to -15.6% over the past ten quarters, as reported in its financial statements, which is typical for a clinical-stage biotech but indicates a complete absence of capital efficiency.
The negative ROE is driven by persistent net losses and is not indicative of operational mismanagement but rather the company's business model, which requires significant upfront investment before any revenue generation. The trend shows no improvement, with losses deepening in recent quarters, confirming that capital is being consumed for R&D rather than generating returns. This metric will remain meaningless until the company achieves a commercial breakthrough.
The Misleading Strength of the Current Ratio
The current ratio, commonly used to assess short-term health, is the most misapplied metric for ZURA, as its high value of 12.90 obscures the fundamental risk of a finite cash runway in a pre-revenue model.
For a company with no revenue and a significant, ongoing cash burn, the current ratio is a poor indicator of financial health. It measures the ability to cover liabilities with current assets at a single point in time but ignores the velocity of cash consumption. A more appropriate metric is the cash runway, calculated by dividing the cash balance by the average quarterly cash burn from operations. This forward-looking measure provides a more accurate assessment of the company's solvency and the potential need for dilutive financing.